Bedaquiline (Sirturo®) is indicated for use as part of an appropriate combination regimen for pulmonary MDR‑TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
|23/01/2015||20/02/2015||Full Pharmacoeconomic Evaluation Not Recommended|
Full HTA not required. The NCPE however recommend that if reimbursed that use of bedaquiline be subject to certain conditions.